Top Longevity Scientists Unite to Map Aging Biomarkers and New Interventions
Elite researchers from Stanford, Harvard, and beyond convened to accelerate aging biomarker discovery and longevity intervention development.
Summary
The TimePie Longevity Forum brought together some of the world's leading aging scientists — including epigenetic clock pioneer Steve Horvath, autophagy expert Ana Maria Cuervo, and genomic instability researcher Jan Vijg — to share progress on aging biomarkers and potential interventions. The forum served as a cross-institutional summit spanning labs in the US, China, and Singapore, aiming to align and accelerate the field. Discussions centered on validated measures of biological age, emerging therapeutic targets, and translational strategies for converting laboratory discoveries into real-world longevity interventions. Published in Nature Aging, this report reflects the growing momentum behind organized, multinational longevity science and signals where the field's sharpest minds believe the highest-impact opportunities lie.
Detailed Summary
Longevity science is rapidly maturing from fragmented discoveries into a coordinated global effort, and the TimePie Longevity Forum represents one of the clearest expressions of that shift. By convening a remarkable roster of leading researchers, the forum aimed to synthesize progress across aging biomarkers and intervention discovery in a single structured setting.
The forum gathered investigators from institutions including Stanford University School of Medicine, Albert Einstein College of Medicine, Harvard Medical School, Tsinghua University, Peking University, and the National University of Singapore, among others. Authors include some of the most cited names in aging science: Steve Horvath, the originator of epigenetic clocks; Ana Maria Cuervo, a pioneer in autophagy and protein homeostasis; Vera Gorbunova and Andrei Seluanov, known for their work on longevity mechanisms in long-lived species; and David Furman, whose inflammatory aging index iAge has attracted clinical interest.
Key themes reported from the forum include advances in biological age measurement — particularly epigenetic, proteomic, and inflammatory clocks — alongside emerging intervention candidates that target core aging hallmarks such as genomic instability, autophagy dysfunction, and epigenetic drift. Translational pathways from preclinical models to human trials were also a focal point.
For clinicians and health-conscious individuals, the forum's output signals which biomarkers and therapeutic strategies the field's leading scientists consider most credible and actionable. It provides a high-level map of where longevity medicine is heading over the next several years.
Important caveats apply: this article is a forum report rather than a primary research study, meaning it synthesizes expert discussion rather than presenting new experimental data. The summary here is based on the abstract alone, as the full text is behind a paywall, limiting granular detail on specific findings or consensus statements reached.
Key Findings
- Elite longevity scientists converged to align on the most promising aging biomarkers, including epigenetic and inflammatory clocks.
- Intervention targets discussed span autophagy, epigenetic reprogramming, and genomic instability — core aging hallmarks.
- Translational strategies to move lab discoveries toward human longevity trials were a central forum priority.
- The forum included iAge co-founder David Furman and epigenetic clock pioneer Steve Horvath, signaling strong biomarker consensus-building.
- Cross-institutional collaboration across the US, China, and Singapore reflects the increasingly global nature of longevity research.
Methodology
This is a forum report published in Nature Aging summarizing presentations and discussions from the TimePie Longevity Forum. It is not a controlled experimental study; it synthesizes expert perspectives from approximately 19 named researchers across multiple institutions. The full methodology of the forum itself — including how sessions were structured or consensus was reached — is not available from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting detail on specific findings or recommendations. As a forum report rather than an experimental study, it carries lower evidentiary weight than a primary research paper or meta-analysis. Several authors have disclosed commercial conflicts of interest in longevity biotech companies, which may influence the framing of priority areas.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: